Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

France’s Ipsen Has Agreements In U.K., U.S.

by Michael McCoy
July 22, 2013 | A version of this story appeared in Volume 91, Issue 29

The Paris-based drug company Ipsen has acquired Syntaxin, an English biotech firm that specializes in botulinum toxin engineering. Ipsen is paying about $37 million up front and could make more than $170 million in future payments to Syntaxin’s owners depending on commercial success. Ipsen and Syntaxin have collaborated since 2010 on neurology drugs based on botulinum toxins. Separately, Ipsen will fund research on engineered botulinum toxins at Harvard Medical School for at least three years.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.